Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio

Apr 27 2018

• By Mandy Jackson and Ian Haydock

Finance Watch

Related Content

G1, Revolution lead $116m in new VC funding

Feb 05 2015

Novartis Buys Selexys As Competitors Stumble In Sickle Cell

Nov 21 2016

All Change At Alexion, But Will It Boost Investor Confidence?

May 24 2017

VC Tally: $1.2bn Invested So Far In 2016 Includes Savara, Corvidia

Mar 02 2016

Tech Transfer Roundup: Janssen, Eisai, Apexian, Innovus And More

Jul 11 2017

Beautiful Mornin' for Oklahoma's Selexys as it bags $665m Novartis option and venture round

Sep 20 2012

Closer To Home: Hong Kong Takes On Nasdaq For China Biotech IPOs

Feb 06 2018

China Roundup: Innovent I/O Setback, Adagene, Hua Bag Millions, WuXi Relisting

Apr 03 2018

Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic

Oct 09 2017

Cell And Gene Therapies: Where Few Standard Rules Apply

Oct 06 2017

VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups

Dec 23 2016

EryDex shows Phase II promise for rare disease ataxia telangiectasia

Mar 02 2012

Related Companies

Alexion Pharmaceuticals Inc.

University of Connecticut

Innovent Biologics, Inc.

Eli Lilly and Company

Tmunity Therapeutics Inc.

Novartis AG

University of Pennsylvania

Corvidia Therapeutics

AstraZeneca PLC

MedImmune LLC

Ipsen SA

Revolution Medicines, Inc.

Cedilla Therapeutics

Takeda Pharmaceutical Co. Ltd.

Cerulean Pharma Inc.

Novartis AG

Tetherex Pharmaceuticals Corporation

Selexys Pharmaceuticals Corporation

Sollis Therapeutics, Inc.

EryDel SpA

X-Chem, Inc.

Harvard University

Grid Therapeutics, LLC

Additional Topics

Financing StartUps and SMEs Rare Diseases Business Strategies Commercial BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window